virulence, viral DNA synthesis, or both, which can limit virus replication to cancer cells and, thus, oHSV specifically destroys only tumor cells. 6 Furthermore, oHSV is not associated with cross-resistance to other therapy strategies, such as chemotherapy. 6 Oncolytic HSV-1 is in phase I-III clinical trials for treating solid tumors. [7] [8] [9] [10] [11] One of the first mutants, oHSV G207, was derived from HSV-1 strain F with deletions in both copies of the c34.5 gene and harbors a lacZ insertion that inactivates the ICP6 gene, which permits replication in cancer cells that can complement these mutations but not in normal cells, including neurons. 12 oHSV T-Vec is a double-mutated HSV-1 with deletions in the c34.5 and a47 genes, and the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene inserted into the deleted c34.5 loci. 10 T-Vec (talimogene laherparepvec) was approved for melanoma by the FDA in the USA and was subsequently approved in Europe and Australia. 13, 14 The mutant G47D was derived from G207 by introducing a third deletion within the a47 gene that overlaps the US11 promoter. [15] [16] [17] [18] [19] [20] Compared with G207, G47D replicates more efficiently and increases the presentation of the MHC class I molecule while maintaining the safety profile of G207. 15 These properties enabled the development of an enhanced cytotoxic lymphocyte response against tumor cells and enhanced the therapeutic efficacy of the virus, as indicated by the results acquired from studies of animal models of brain tumors. 15 Furthermore, Fukuhara et al 5 demonstrate that an induction of specific antitumor immunity in the course of oncolytic activities plays an important role in presenting antitumor effects.
In the present study, we used T-01, 21 which has a genomic structure similar to that of G47D. In T-01, the a47 and c34.5 loci are deleted and the LacZ gene replaces the ICP6 gene. Deletion of the a47 loci enhanced antitumor immune responses following treatment. 21 We examined the antitumor activities of T-01 in HCC cell lines and mouse tumor xenograft models, and evaluated the host's immune response to HCC cells. and the transfected cells were named HuH-7-luc, KYN2-luc and HepG2-luc.
| MATERIALS AND METHODS

| Cell lines
The details for constructing the T-01 as HSV-1 mutant are as published previously. 21 Virus stocks were purified and concentrated as described with minor modifications. 22 
| Animals
Five-week-old male C57BL/6 mice and athymic mice (BALB/c nu/ nu) were purchased from Japan SLC (Shizuoka, Japan) and used in experiments at 6 weeks of age. All mice were caged in groups of 4 or fewer. Mice were anesthetized with an intraperitoneal injection of pentobarbital. The mouse studies were conducted according to the guidelines approved by the Animal Care and Use Committee of Kansai Medical University.
| In vitro cytotoxicity and virus replication assay
Assays were performed as previously described. 17, 21 Briefly, cells were infected with virus or mock for 1 hour and incubated at 37°C
in DMEM supplemented with 1% heat-inactivated FBS. The number of surviving cells (cytotoxicity) was expressed as a percentage of the mock-infected controls. Cells were infected with T-01 at a multiplicity of infection (MOI) = 0.01 and incubated at 37°C for 48 hours.
The titer of the progeny virus stock was determined using a plaque assay with Vero cells. Each experiment was performed in triplicate.
| Therapy of subcutaneous tumors
Tumors were generated by subcutaneously injecting tumor cells 
| Analysis of CD4 and CD8 expression
Mice were killed 14 days after virus or mock inoculation, and subcutaneous Hepa1-6 tumor tissues and spleens were embedded in optimal cutting temperature compound and frozen in liquid nitrogen.
Sections ( 
| ELISPOT assay
Assays were performed according to the manufacturer's protocols ) were added to the plate and then effector Hepa1-6 cells (5 9 10 5 ) or untreated controls and target cells were added to the plate, which was then incubated for 24 hours at 37°C in an atmosphere containing 5% CO 2 . The number of spots was automatically counted using an Eliphoto system (Minerva Tech, Tokyo, Japan).
| Rechallenge studies
Mice with established subcutaneous tumors formed by Hepa1-6 cells and regressed cells after treatment using T-01 (2 9 10 6 pfu, twice)
as well as age-matched na€ ıve male C57BL/6 mice were rechallenged with Hepa1-6 cells. Hepa1-6 cells (5 9 10 6 ) were injected subcutaneously into the back, and tumor growth was observed as described previously. 21 The animals were observed for 60 days.
| Safety evaluation of T-01 when injected to the liver
To evaluate safety of T-01, T-01 (2 9 10 6 pfu) in 20 lL of PBS containing 10% glycerol or mock preparation was injected into the left lobe of the liver of athymic mice. Mice were monitored for clinical manifestations daily for 7 days (n = 3). The mice were killed 1 week after the injection of T-01 or mock preparation and were subjected to analyses of serum and pathology. Before killing the mice, the blood was collected in the ophthalmic vein. Serum aspartate aminotransferase, alanine aminotransferase, c-glutamyltranspeptidase, amylase, alkaline phosphatase and lactate dehydrogenase were analyzed using commercial kits (Wako Pure Chemicals, Osaka, Japan).
Serum urea nitrogen and creatinine were measured with Denka Seiken (Tokyo, Japan) and Alfresa Pharma (Osaka, Japan) commercial kits, respectively.
Body weight was evaluated at the start of treatment and upon death. Liver, lungs and kidneys were excised, fixed in formaldehyde, and embedded in paraffin for histological analysis.
| Statistical analysis
All data are expressed as the mean AE SEM. The in vitro data and in vivo tumor-volume data were evaluated using an unpaired t-test.
Overall survival was estimated using the Kaplan-Meier method, and the data were compared using the log-rank test. P < .05 was considered statistically significant.
3 | RESULTS
| Cytopathic effects of T-01 and virus yields in vitro
We first examined the effects of T-01 on a panel of human HCC We also examined virus yields in the cell lines and found that the virus yields increased in most cells, except for JHH-5 and JHH-7 cells (unchanged) and HLE and JHH-2 cells (decreased) (Figure 2 ).
The cell lines used in these assays and the data are summarized (Table S1 ).
| Effects of T-01 in mice with subcutaneous tumors
The efficacy of T-01 was tested in athymic mouse models with subcutaneous tumors that were generated using human HCC and HBC cell lines (Figure 3 ). HuH 
| Effects of T-01 on orthotopic tumors
We examined the effects of T-01 on orthotopic tumors induced by 
| Effect of T-01 on peritoneal metastases
We established peritoneal metastatic tumors in athymic or C57BL/6 mice implanted with KYN-2-Luc or Hepa1-6 cells, and inoculated 
| Safety of intrahepatic inoculation of T-01
To determine whether intrahepatic inoculation of T-01 induced cytotoxicity, we used BALB/c nu/nu mice because BALB/c mice are more susceptible to HSV-1 infection compared with C57BL/6 mice.
BALB/c nu/nu mice were inoculated intrahepatically with mock preparation or T-01 (2 9 10 6 pfu) and monitored daily for clinical manifestations for 7 days. All mock-inoculated and T-01-inoculated mice survived without any detectable abnormalities, and there were no significant differences in blood analysis data between groups (Table S3) . Furthermore, there were no significant differences in the body weights and HE staining data of liver, lungs and kidneys between mock-inoculated and T-01-inoculated mice (data not shown). Next, we examined the antitumor effect of T-01 using an orthotopic model that reflects clinical conditions (Figure 4 ). Furthermore,
| DISCUSSION
we examined the effects of T-01 on a mouse model of peritoneal dissemination using KYN-2 cells ( Figure 5A,B) , because poorly differentiated adenocarcinomas frequently disseminate to the peritoneum. Ascites frequently accumulate in patients with peritoneal metastasis, and ascites fluid is expected to be rich in anti-HSV antibodies, because its immunoglobulin G content reflects that of blood. 37 We examined the effects of T-01 on peritoneal dissemination in an immunocompetent mouse strain engrafted with Hepa1-6 cells ( Figure 5C ). Moreover, a model of orthotopic or peritoneal metastasis is likely more informative compared with a model of a subcutaneous tumor. In our next study, we will confirm the antitumor efficacy and safety of T-01 by using fresh tissue of clinical tumor material, to ensure adequate clinical applications. 38 The significant efficacy and safety in preclinical models can appear the therapeutic benefits. We will confirm the antitumor efficacy and safety of Oncolytic HSV-1 vectors harbor mutations in the viral genome that restrict viral replication to tumor cells, and, therefore, oHSV kills the host tumor cells without harming normal tissue. 14 G47D
was as safe as G207 at the tested dose (2 9 10 6 pfu) when inoculated in the brain of an AJ mouse. 15 AJ is one of the inbred mouse strains most susceptible to HSV-1 infection, particularly compared with BALB/c mice. 30 Despite the toxicity of intraperitoneally inoculated wild-type HSV-1 to BALB/c mice, 30 our results
showed that T-01 did not detectably harm normal tissues (Table S3) . Oncolytic viruses cannot replicate in normal cells, and T-01 is, therefore, nontoxic when inoculated into the liver of nu/ nu BALB/c mice. Treatment for HCC depends on the stage of the tumor and the degree of liver dysfunction. In the clinical, the patients with HCC were derived from HBV and/or HCV infection, which coexist in comorbid liver cirrhosis. T-01 has not posed a safety concern; thus, it might be used not only normal liver but also for hepatitis and cirrhosis. In our next study, we will confirm the safety of T-01 by using animal models of liver cirrhosis and chronic hepatitis.
"Arming" oHSV with transgene(s) is a useful strategy to add certain antitumor functions to oncolytic viruses. strategy to enhance the efficacy of oncolytic viruses. 5 In our current study, the antitumor efficacy of T-01 was confirmed as a base oHSV for "arming," and investigating the efficacy of "arming" oHSV with immune check-point inhibitors.
The safety and increased presentation of MHC class I molecules associated with a third-generation oHSV shows that the oHSV is useful as a backbone vector for expressing foreign antigens in the context of vaccination. In conclusion, our study demonstrates that T-01 effectively inhibited the growth of human HCC and HBC cells in mouse models of HCC. 
